Abstract
Aim:
To describe drugs used in renal cell carcinoma.
Method:
Pubmed search for efficacy, mode of action and side effects for each molecule. Additional data were searched from the French regulatory agencies websites (HAS and ANSM).
Results:
Since 2007, a total of three different therapeutic classes in the management of metastatic renal cell carcinoma are available. These three classes are tyrosine kinase inhibitors with sunitinib and sorafenib, the anti-VEGF antibodies (bevacizumab which is associated with alpha interferon in the treatment of advanced kidney cancer) and mTOR inhibitors with temsirolimus and everolimus. These targeted therapies are a major progress in the treatment of patients with metastatic kidney cancer. The side effects encountered with these molecules are numerous but serious side effects are less than 5% of all reported side effects.
Conclusions:
A better understanding of molecular mechanisms has enabled the development of new therapies for the treatment of metastatic renal cell carcinoma. In the future, a personalized approach taking into account the biology of each tumor could be created to provide a more targeted treatment.
Keywords:
Anti-VEGF antibodies; Anticorps anti-VEGF; Cancer du rein; Inhibiteur de mTOR; Inhibiteur des tyrosines kinases; MTOR inhibitor; Renal cell carcinoma; Targeted therapy; Thérapie ciblée; Tyrosine kinase inhibitor.
Copyright © 2013. Published by Elsevier Masson SAS.
MeSH terms
-
Angiogenesis Inhibitors / pharmacology
-
Angiogenesis Inhibitors / therapeutic use
-
Antibodies, Monoclonal, Humanized / pharmacology
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Antineoplastic Agents / pharmacology*
-
Antineoplastic Agents / therapeutic use
-
Bevacizumab
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / pathology
-
Everolimus
-
Humans
-
Immunotherapy
-
Indoles / pharmacology
-
Indoles / therapeutic use
-
Interferon alpha-2
-
Interferon-alpha / pharmacology
-
Interferon-alpha / therapeutic use
-
Interleukin-2 / analogs & derivatives
-
Interleukin-2 / pharmacology
-
Interleukin-2 / therapeutic use
-
Kidney Neoplasms / drug therapy*
-
Kidney Neoplasms / pathology
-
Neoplasm Metastasis / drug therapy
-
Niacinamide / analogs & derivatives
-
Niacinamide / pharmacology
-
Niacinamide / therapeutic use
-
Phenylurea Compounds / pharmacology
-
Phenylurea Compounds / therapeutic use
-
Protein Kinase Inhibitors / pharmacology
-
Protein Kinase Inhibitors / therapeutic use
-
Pyrroles / pharmacology
-
Pyrroles / therapeutic use
-
Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
-
Recombinant Proteins / pharmacology
-
Recombinant Proteins / therapeutic use
-
Sirolimus / analogs & derivatives
-
Sirolimus / pharmacology
-
Sirolimus / therapeutic use
-
Societies, Medical
-
Sorafenib
-
Sunitinib
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Indoles
-
Interferon alpha-2
-
Interferon-alpha
-
Interleukin-2
-
Phenylurea Compounds
-
Protein Kinase Inhibitors
-
Pyrroles
-
Recombinant Proteins
-
Vascular Endothelial Growth Factor A
-
Niacinamide
-
Bevacizumab
-
temsirolimus
-
Everolimus
-
Sorafenib
-
Receptors, Vascular Endothelial Growth Factor
-
aldesleukin
-
Sunitinib
-
Sirolimus